Literature DB >> 16999955

VIP is a transcriptional target of Nurr1 in dopaminergic cells.

Yu Luo1, Leigh A Henricksen, Rita E Giuliano, Llanda Prifti, Linda M Callahan, Howard J Federoff.   

Abstract

The orphan nuclear receptor Nurr1 is required for the development of the ventral mesencephalic dopaminergic neurons. These are the same neurons that are invariantly lost in patients with Parkinson's disease. Nurr1 mRNA expression is not confined to the developing midbrain, and yet Nurr1 appears to be essential for either the maturation of progenitors into fully post-mitotic dopaminergic neurons and/or once formed, their survival. The function of Nurr1 in the transactivation of gene(s) important for neuronal development and/or maintenance is uncharacterized. To characterize potential downstream target genes of Nurr1, we sought to identify mRNAs that are differentially affected by Nurr1 expression. Using a dopaminergic cell line in which Nurr1 content was tightly regulated, differential display analysis identified transcripts altered by Nurr1 expression, including the mRNA encoding vasoactive intestinal peptide (VIP). Herein, we demonstrate that Nurr1 regulates VIP mRNA and protein levels, and transactivates the VIP promoter through Nurr1-responsive cis elements. In addition, dopaminergic cells release and utilize VIP to mediate survival when challenged with paraquat. Nurr1 regulation of VIP is also demonstrated in vivo as loss of Nurr1 function results in diminished VIP mRNA levels within the developing midbrain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16999955     DOI: 10.1016/j.expneurol.2006.08.005

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  18 in total

1.  Structure-dependent activation of NR4A2 (Nurr1) by 1,1-bis(3'-indolyl)-1-(aromatic)methane analogs in pancreatic cancer cells.

Authors:  Xi Li; Syng-Ook Lee; Stephen Safe
Journal:  Biochem Pharmacol       Date:  2012-03-03       Impact factor: 5.858

Review 2.  Structure-dependent activation of gene expression by bis-indole and quinoline-derived activators of nuclear receptor 4A2.

Authors:  Xi Li; Ronald B Tjalkens; Rupesh Shrestha; Stephen Safe
Journal:  Chem Biol Drug Des       Date:  2019-07-21       Impact factor: 2.817

Review 3.  NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.

Authors:  Mickael Decressac; Nikolaos Volakakis; Anders Björklund; Thomas Perlmann
Journal:  Nat Rev Neurol       Date:  2013-10-15       Impact factor: 42.937

4.  Dopamine and paraquat enhance α-synuclein-induced alterations in membrane conductance.

Authors:  Li Rebekah Feng; Kathleen A Maguire-Zeiss
Journal:  Neurotox Res       Date:  2011-07-07       Impact factor: 3.911

Review 5.  Nurr1-Based Therapies for Parkinson's Disease.

Authors:  Jie Dong; Song Li; Jing-Lin Mo; Huai-Bin Cai; Wei-Dong Le
Journal:  CNS Neurosci Ther       Date:  2016-03-25       Impact factor: 5.243

Review 6.  Future directions for immune modulation in neurodegenerative disorders: focus on Parkinson's disease.

Authors:  Kathleen A Maguire-Zeiss; Howard J Federoff
Journal:  J Neural Transm (Vienna)       Date:  2010-06-12       Impact factor: 3.575

7.  Nurr1 protein is required for N-methyl-D-aspartic acid (NMDA) receptor-mediated neuronal survival.

Authors:  Bruna Barneda-Zahonero; Joan-Marc Servitja; Nahuai Badiola; Alfredo J Miñano-Molina; Rut Fadó; Carlos A Saura; José Rodríguez-Alvarez
Journal:  J Biol Chem       Date:  2012-01-31       Impact factor: 5.157

8.  Vesicular monoamine transporter 2 and dopamine transporter are molecular targets of Pitx3 in the ventral midbrain dopamine neurons.

Authors:  Dong-Youn Hwang; Sunghoi Hong; Joo-Won Jeong; Sangdun Choi; Hansoo Kim; Jangwoo Kim; Kwang-Soo Kim
Journal:  J Neurochem       Date:  2009-09-24       Impact factor: 5.372

9.  Ontogenetic expression of dopamine-related transcription factors and tyrosine hydroxylase in prenatally stressed rats.

Authors:  Maria R Katunar; Trinidad Saez; Alicia Brusco; Marta C Antonelli
Journal:  Neurotox Res       Date:  2009-11-20       Impact factor: 3.911

10.  Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease.

Authors:  Liang Huang; Mika Shimoji; Juan Wang; Salim Shah; Sukanta Kamila; Edward R Biehl; Seung Lim; Allison Chang; Kathleen A Maguire-Zeiss; Xiaomin Su; Howard J Federoff
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.